Literature DB >> 582111

[Chloroquine enantiomers. Activity against P. vinckei and binding on DNA (author's transl)].

E Fink, G Minet, P Nickel.   

Abstract

(+)-Chloroquine is more active against P. vinckei than (-)-chloroquine. No correlation has been observed between antiplasmodial activity and DNA-binding of the chloroquine enantiomers.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 582111

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN： 0004-4172


  7 in total

1.  In vitro activity of chloroquine, the two enantiomers of chloroquine, desethylchloroquine and pyronaridine against Plasmodium falciparum.

Authors:  S Fu; A Björkman; B Wåhlin; D Ofori-Adjei; O Ericsson; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 3.  Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications.

Authors:  S Krishna; N J White
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

4.  Stereoselective inhibition by chloroquine of histamine N-methyltransferase in the human liver and brain.

Authors:  P Donatelli; G Marchi; L Giuliani; L L Gustafsson; G M Pacifici
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

5.  Stereoselective pharmacokinetic properties of chloroquine and de-ethyl-chloroquine in humans.

Authors:  P Augustijns; N Verbeke
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

6.  Disposition of the enantiomers of hydroxychloroquine in patients with rheumatoid arthritis following multiple doses of the racemate.

Authors:  A J McLachlan; S E Tett; D J Cutler; R O Day
Journal:  Br J Clin Pharmacol       Date:  1993-07       Impact factor: 4.335

Review 7.  Clinical pharmacokinetics of slow-acting antirheumatic drugs.

Authors:  S E Tett
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.